The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 21, 2021
Filed:
Nov. 04, 2016
Applicant:
Acceleron Pharma Inc., Cambridge, MA (US);
Inventors:
Ravindra Kumar, Acton, MA (US);
Pedro Martinez, Cambridge, MA (US);
Naga Venkata Sai Rajasekhar Suragani, Wrentham, MA (US);
Assignee:
ACCELERON PHARMA INC., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); A61K 38/17 (2006.01); C07K 14/71 (2006.01); C07K 14/705 (2006.01); A61P 7/06 (2006.01); A61K 45/06 (2006.01); A61K 31/192 (2006.01); A61K 31/565 (2006.01); A61K 31/136 (2006.01); A61K 31/365 (2006.01); A61K 31/138 (2006.01); A61K 31/704 (2006.01); A61K 31/4155 (2006.01); A61K 31/46 (2006.01); A61K 31/395 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); C07K 16/22 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61K 31/136 (2013.01); A61K 31/138 (2013.01); A61K 31/192 (2013.01); A61K 31/365 (2013.01); A61K 31/395 (2013.01); A61K 31/4155 (2013.01); A61K 31/46 (2013.01); A61K 31/565 (2013.01); A61K 31/704 (2013.01); A61K 38/00 (2013.01); A61K 38/1709 (2013.01); A61K 38/179 (2013.01); A61K 38/18 (2013.01); A61K 39/395 (2013.01); A61P 7/06 (2018.01); C07K 14/705 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01);
Abstract
In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subjects having anemia and/or ineffective erythropoiesis as a result of having reduced GATA-1, heat shock factor and/or NFE2 levels as compared to the levels in a reference population.